TABLE 3.

Stratified Analysis by Receipt of Neoadjuvant Therapy

	No Neoadjuvant Therapy (n = 1993)			Neoadjuvant Therapy (n = 415)
	TR	95% CI	P	TR	95% CI	P
Sex
Male		Reference			Reference
Female	1.05	(0.93–1.18)	0.448	1.04	(0.81–1.33)	0.752
Procedure type
Proximal pancreatectomy		Reference			Reference
Distal pancreatectomy	1.13	(0.65–1.97)	0.653	3.53	(1.21–10.24)	0.021
Radical antegrade pancreaticosplenectomy	0.69	(0.31–1.51)	0.352	2.00	(0.48–8.35)	0.342
Other partial pancreatectomy	1.11	(0.60–2.05)	0.750	0.95	(0.28–3.20)	0.928
Total pancreatectomy	1.02	(0.55–1.88)	0.949	2.83	(0.90–8.92)	0.076
Whipple	0.99	(0.57–1.70)	0.961	2.70	(0.95–7.65)	0.062
Age	1.01	(1.00–1.02)	0.018	1.02	(1.00–1.04)	0.043
Complications during index hospitalization
None		Reference			Reference
1	0.91	(0.79–1.06)	0.221	0.94	(0.71–1.24)	0.670
2 or more	0.68	(0.46–1.01)	0.053	0.54	(0.28–1.06)	0.072
Charlson Co-morbidity Index
≤2		Reference			Reference
>2	0.74	(0.63–0.87)	<0.001	1.16	(0.80–1.68)	0.424
Nodal Involvement	0.73	(0.62–0.87)	<0.001	0.74	(0.51–1.06)	0.102
Chemotherapy
Gemcitabine	1.23	(0.86–1.77)	0.250	1.25	(0.76–2.05)	0.378
Gemcitabine + nab-paclitaxel	1.32	(1.01–1.72)	0.044	1.19	(0.81–1.74)	0.382
FOLFIRINOX	1.21	(0.94–1.57)	0.134	0.94	(0.66–1.32)	0.712
Oxaliplatin	1.02	(0.76–1.38)	0.880	0.90	(0.61–1.33)	0.587
Capecitabine	1.02	(0.84–1.24)	0.851	1.21	(0.90–1.62)	0.203
Erlotinib	0.90	(0.60–1.35)	0.619	0.72	(0.45–1.15)	0.164
Radiation therapy
Radiation without concurrent infusion	1.25	(1.05–1.50)	0.013	0.98	(0.63–1.53)	0.943
Radiation with 5-FU	0.77	(0.64–0.94)	0.009	1.00	(0.72–1.38)	0.993
Radiation with gemcitabine	0.74	(0.51–1.08)	0.115	0.98	(0.57–1.69)	0.951

5-FU indicates 5-fluorouracil; CI, confidence interval; FOLFIRINOX, folinic acid, 5-fluorouracil, irinotecan, oxaliplatin; TR, time ratio. For variables used as indicators of ever-receipt of certain chemotherapy or radiation regimens, the reference category is non-receipt of that chemotherapy or radiation therapy.